Research programme: immunological disorder therapeutics - Entrada Therapeutics
Latest Information Update: 03 Oct 2024
At a glance
- Originator Entrada Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Immunological disorders
Most Recent Events
- 02 Sep 2024 Early research in Immunological disorders in USA (unspecified route) prior to September 2024 (Entrada Therapeutics pipeline, September 2024)